Navigation Links
GSK and Amicus Therapeutics Enter Exclusive Worldwide Agreement to Develop and Commercialize Amigal™ for Fabry Disease
Date:10/29/2010

LONDON and CRANBURY, N.J., Oct. 29 /PRNewswire/ -- GlaxoSmithKline PLC (GSK) and Amicus Therapeutics (Nasdaq: FOLD) today announced a definitive agreement to develop and commercialize Amigal (migalastat HCl), currently in Phase 3 for the treatment of Fabry disease, a rare inherited disorder.  Under the terms of the agreement, GSK will receive an exclusive worldwide license to develop, manufacture and commercialize migalastat HCl.  Additionally, as part of the agreement GSK and Amicus also intend to advance clinical studies exploring the co-administration of migalastat HCl with enzyme replacement therapy (ERT) for the treatment of Fabry disease. 

Under the terms of the Agreement, Amicus will receive an upfront, license payment of $30M from GSK and is eligible to receive further payments of approximately $170M upon the successful achievement of development and commercialization milestones, as well as tiered double-digit royalties on global sales of migalastat HCl. GSK and Amicus will jointly fund development costs in accordance with an agreed upon development plan.   Additionally, as part of the collaboration, GSK is purchasing 6.9 million shares of Amicus common stock at a price of $4.56 per share.  The total value of this equity investment to Amicus is $31 million and represents a 19.9% ownership position for GSK in the Company.  The total cash up-front to Amicus from GSK for the upfront license payment and equity investment is approximately $60 million.

"This strategic collaboration is another significant milestone in delivering our vision for GSK Rare Diseases. Amicus' scientific and clinical expertise in human genetic diseases is among the best in the industry, and we are pleased to be collaborators and investors in this exceptional company," said Marc Dunoyer, Global Head of GSK Rare Diseases and a member of the GSK Corp
'/>"/>

SOURCE Amicus Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
2. Amicus Therapeutics Announces Plans to Present Phase 1 Data for AT2220 for Pompe Disease
3. Amicus Therapeutics Announces Positive Results From Two Phase 1 Clinical Studies of AT2220 for Pompe Disease
4. Amicus Therapeutics to Present at the 26th Annual JPMorgan Healthcare Conference
5. Amicus Therapeutics Presents Data from Clinical Ex Vivo Response Study and Phase 1 Studies of AT2220
6. Amicus Therapeutics Begins Phase 2 Clinical Trial of AT2220 in Pompe Disease
7. Amicus Therapeutics Announces Successful Completion of End of Phase 2 Meeting With FDA for Amigal in Fabry Disease
8. Amicus Therapeutics Announces Second Quarter 2008 Financial Results
9. Amicus Therapeutics Announces Positive Progress of Three Lead Clinical Programs and General Outlook for 2009
10. Amicus Therapeutics Suspends Enrollment for Phase 2 Clinical Trial of AT2220 for Pompe Disease
11. Amicus Therapeutics Announces Issuance of New Plicera(TM) Composition of Matter Patent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... , Sept. 30, 2014 Aileron ... Summary Global Markets Direct,s, ,Aileron Therapeutics, ... an overview of the Aileron Therapeutics, Inc.,s pharmaceutical ... comprehensive information on the current therapeutic developmental pipeline ... at various stages, therapeutics assessment by drug target, ...
(Date:9/30/2014)... Mass. , Sept. 30, 2014  Decision Resources Group finds ... Australia , China , ... Korea—will expand at a strong rate through 2023. Dental implant procedure ... and as patient awareness rises. Other key findings from ... dental implant market: , Dental implant penetration: ...
(Date:9/30/2014)... 30, 2014 According ... Market by Product [Enzymes (Glycosyltransferase, Neuraminidase, Glycosidase), ... Reagents], Application (Immunology, Oncology) & by End ... by MarketsandMarkets, provides a detailed overview of ... market trends, and strategies impacting the global ...
Breaking Medicine Technology:Aileron Therapeutics, Inc. - Product Pipeline Review - 2014 2Aileron Therapeutics, Inc. - Product Pipeline Review - 2014 3Asia Pacific Dental Implant Market Will Grow at a Strong Rate Through 2023 2Asia Pacific Dental Implant Market Will Grow at a Strong Rate Through 2023 3Glycobiology / Glycomics Market Worth $928.11 Million by 2019 2Glycobiology / Glycomics Market Worth $928.11 Million by 2019 3Glycobiology / Glycomics Market Worth $928.11 Million by 2019 4
... 25, 2012 The Department of Justice, on behalf of ... consent decree of permanent injunction against generic drug manufacturer ... consent decree was filed against Ranbaxy Laboratories, Ltd., an ... N.J. Ranbaxy Labs., Dale Adkisson, senior vice president, head ...
... 2012  Covance Inc. (NYSE: CVD ) said ... repurchase of up to $300 million of its outstanding ... approximately 800,000 shares remaining under a previously-announced repurchase authorization ... common stock. Any purchases under this buyback would be ...
Cached Medicine Technology:Department of Justice files consent decree of permanent injunction against Ranbaxy 2Department of Justice files consent decree of permanent injunction against Ranbaxy 3Department of Justice files consent decree of permanent injunction against Ranbaxy 4Covance Board Authorizes $300 Million Stock Buyback 2
(Date:9/30/2014)... UC Irvine immunologists reveals new information about how our ... that determines how the body,s ability to fight infection ... Immunology , neurology professor Dr. Michael Demetriou, postdoctoral scholar ... a critical mechanism underlying how T cells are created, ... cell is a type of blood cell called a ...
(Date:9/30/2014)... September 30, 2014 EverStryke , the ... introduction to SurvivalLife.com along with a free book and class ... of Shane Michaels, prompting an investigative review. , “Joe ... in the survival and preparation niche, and this product is ... great classes and survival products that Joe offers on his ...
(Date:9/30/2014)... September 30, 2014 VisitandCare.com ... Turkey has gone up more than 79 percent in ... tourism company also reported total revenue tripled for its ... The company’s professional strategy has allowed them to partner ... designed for patient comfort and privacy — with state-of-the-art ...
(Date:9/30/2014)... Regenerative Medicine Solutions (RMS) is set ... Nashville, Tennessee. RMS welcomes the launch of an entirely ... of a new treatment center for the Lung Institute. ... Institute to Nashville, the hope is to bring awareness ... diagnosed and undiagnosed. With Nashville being a hub for ...
(Date:9/30/2014)... (PRWEB) September 30, 2014 Bifidobacteria, the ... with age, poor diet, and stress, so a high ... Each capsule of Ultimate Flora™ Men’s Complete ... cultures from 7 Bifidobacteria strains to support a healthy ... to build up, and 32 billion cultures from 7 ...
Breaking Medicine News(10 mins):Health News:UCI study uncovers important process for immune system development 2Health News:EverStryke: Review Exposes Joe Marshall’s Permanent Match Survival Product 2Health News:VisitandCare.com Announces Record Demand for Plastic Surgery in Turkey 2Health News:VisitandCare.com Announces Record Demand for Plastic Surgery in Turkey 3Health News:VisitandCare.com Announces Record Demand for Plastic Surgery in Turkey 4Health News:Regenerative Medicine Solutions Expanding 2Health News:ReNew Life Introduces Ultimate Flora™ Men’s Complete Probiotic 90 Billion—Comprehensive Probiotic Support Just for Men 2
... are reminded to protect their eyes and skin ... dangerous UV rays on and off the field, PINELLAS PARK, ... eagerly awaited time to enjoy outdoor sports and activities.,However, many forget ... practice outdoor sports -- particularly in the summer,-- are conscious of ...
... July 29 On October 30, millions of breast,cancer ... glasses in a "Toast to the Cure.", This ... by breast cancer to memorialize those friends and family ... the stories of,survivors, commending cause advocates, thanking supporters, and ...
... Despite Experiencing Leg Pain and ... Discomfort, ... legs -- force many embarrassed sufferers to cover up, even on,the hottest ... develop into serious health problems. According,to a new survey, many who suffer ...
... found that cerebral malaria is related to long-term cognitive impairment in ... current issue of the journal Pediatrics . , ... is a leading cause of death for children in sub-Saharan Africa. ... is one of the deadliest forms of malaria. It only takes ...
... ANNAPOLIS, Md., July 29 RiskWatch, Inc. announced ... RWSURVEY,available http://www.rwsurvey.com ., The web-based software allows ... surveys online and includes compliance surveys for:, ... PCI HIPAA Compliance BSA-AML ISO 27001 ...
... July 29 American Imaging Management (AIM), an,operating ... and leading imaging,benefit management and technology company with ... that it has reached an,agreement to provide diagnostic ... of Vermont (BCBSVT)., "As a company that ...
Cached Medicine News:Health News:Transitions Optical Offers Tips on How to Protect Eyes for Outdoor Sports Fans 2Health News:Video: A 'Toast to the Cure' Set for October 30 Breast Cancer Survivors 'Raise Your Glasses' 2Health News:Survey Shows People With Varicose Veins Unaware of Health Risks; Most Never Consider Treatment 2Health News:Survey Shows People With Varicose Veins Unaware of Health Risks; Most Never Consider Treatment 3Health News:Survey Shows People With Varicose Veins Unaware of Health Risks; Most Never Consider Treatment 4Health News:U of M researchers find cerebral malaria may be a major cause of brain injury in African children 2Health News:New Web-Based Compliance Program Released by RiskWatch 2Health News:American Imaging Management Partners with Blue Cross and Blue Shield of Vermont 2
... is the first hernia repair material ... operative contamination of the material. This ... preservative agents, silver carbonate and chlorhexidine ... colonization on the patch for up ...
... in 1958, Bard mesh has become the ... compared. Bard mesh was used by Dr. ... "tension-free" hernia repair many years ago. Lichtenstein ... ideal" substance for permanent reinforcement of hernia ...
... PerFix plug technique, recommended for the ... indirect and direct inguinal hernias, provides ... technique, requiring less overall dissection and ... repair technique. The result is increased ...
... is a compact, highly portable, single wavelength ... integrated StarPulse feature enables the treatment of ... leg and face, and pigmented surface lesions, ... used as a continuous wave laser for ...
Medicine Products: